Advertisement

Digestive Diseases and Sciences

, Volume 43, Issue 4, pp 893–897 | Cite as

Chronic Splanchnic Hemodynamic Effects of Spironolactone with Unrestricted Sodium Diet in Patients with Compensated Cirrhosis

  • Shigeo Sugano
  • Takashi Kawafune
  • Tugio Okajima
  • Kunihiko Ishii
  • Manabu Watanabe
  • Naoko Takamura
Article

Abstract

The purpose of this study is to determine thehemodynamic effects of spironolactone administrationassociated with an unrestricted sodium diet (salt 10 g)in patients with compensated cirrhosis and portal hypertension. We studied the hemodynamicchanges following eight weeks of administration ofeither placebo (N = 6) or spironolactone (100 mg/day) (N= 6 Pugh-Child's A and 6 B). No significant changes were observed after the administration of theplacebo. Spironolactone induced a significant reductionin the hepatic venous pressure gradient (HVPG)(–10.1 ± 13.3%, P < 0.05), which wasassociated with a significant reduction of cardiac output(–11.5 ± 9.3%, P < 0.01), plasma volume(–8.1 ± 4.7%, P< 0.01), and wedgedhepatic venous pressure (–10.5 ± 11.6%, P< 0.05). There was no significant change in hepatic blood flow and there was nosignificant correlation between the change in the HVPGand the change in circulating plasma volume. A decreasein the HVPG greater than 10% was observed in eight of 12 patients (67%), defined asresponders, at eight weeks. Six of six (100%) grade Apatients and two of six (33%) grade B patientsresponded. This study demonstrated that spironolactonewith an unrestricted sodium diet decreased the HVPG ingrade A patients but did not significantly decrease theHVPG in grade B patients.

LIVER CIRRHOSIS PORTAL HYPERTENSION HEPATIC VENOUS PRESSURE GRADIENT SPIRONOLACTONE SODIUM DIET 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, Ohsuga M, Komeichi H, Tsutsui H: Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 86:46-52, 1991Google Scholar
  2. 2.
    García-Pagaán JC, Salmerón JM, Feu F, Luca A, Gineés P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J, Rodeés J: Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 19:1095-1099, 1994Google Scholar
  3. 3.
    Pugh RNH, Murray-lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophage al varices. Br J Surg 60:646-649, 1973Google Scholar
  4. 4.
    Villeneuve JP, Huot R, Marleau D, Huet PM: The estimation of hepatic blood flow with indocyanine green: Comparison between the continuous infusion and single injection methods. Am J Gastroente rol 77:233-237, 1982Google Scholar
  5. 5.
    Wiegand BD, Ketterer SG, Rapaport E: The use of indocyanine green for the evaluation of hepatic function and blood flow in man. Am J Dig Dis 5:427-436, 1960Google Scholar
  6. 6.
    Sugano S, Kawafune T, Suzuki T, Kubota M, Okajima T, Sumino Y, Akita H: Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new ß-blocker with nitrovasodilating properties in patients with liver cirrhosis. Am J Gastroenterol 90:788-793, 1995Google Scholar
  7. 7.
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, Rofe S, Patrick M, Lerner E: Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 99:1401- 1407, 1990Google Scholar
  8. 8.
    Lieberman FL, Reynolds TB: Plasma volume in cirrhosis of the liver: Its relation to portal hype rtension, ascites, and renal failure. J Clin Invest 46:1297-1308, 1967Google Scholar
  9. 9.
    Colombato LA, Albillos A, Groszmann RJ: Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 15:323-328, 1992Google Scholar
  10. 10.
    Kravetz D, Sikuler E, Groszmann RJ: Splanchnic and systemic hemodynamics in portal hype rtensive rats during hemorrhage and blood volume restitution. Gastroenterology 90:1232-1240, 1986Google Scholar
  11. 11.
    Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P: Spironolactone inhibition of contraction and calcium channe ls in rat portal vein. Br J Pharmacol 92:535-544, 1987Google Scholar
  12. 12.
    Mironneau J: Calcium channel antagonist effects of spironolactone, an aldosterone antagonist. Am J Cardiol 65:7K-8K, 1990Google Scholar
  13. 13.
    Reynolds TB, Ito S, Iwatsuki S: Measurement of portal pressure and its clinical application. Am J Med 49:649-657, 1970Google Scholar
  14. 14.
    Iwao T, Toyonaga A, Ikegami M, Sumino M, Oho K, Sakaki M, Shigemori H, Nakayama M, Tanikawa K: Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in nonalcoholic cirrhosis. Dig Dis Sci 39:2439-2444, 1994Google Scholar
  15. 15.
    Bosch J, Bordas JM, Mastai R, Kravetz D, Navasa N, Chesta J, Pizcueta MP, Garcia-Pagan JC, Rodes J: Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. Hepatology 8:861- 865, 1988Google Scholar
  16. 16.
    Nevens F, Lijnen P, VanBilloen H, Fevery J: The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 23:1047-1052, 1996Google Scholar
  17. 17.
    Bosch J, Masti R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodes J: Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 4:1200-1205, 1984Google Scholar
  18. 18.
    Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJC, Morse SS, Alberts JL: Short-term effects of propranolol on portal venous pressure. Hepatology 6:101-106, 1986Google Scholar
  19. 19.
    Lebrec D, Hillon P, Muńoz C, Goldfarb G, Nouel O, Benhamou JP: The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 2:523-527, 1982Google Scholar
  20. 20.
    Sugano S, Suzuki T, Nishio M, Makino H, Okajima T: Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Dig Dis Sci 42:529-535, 1997Google Scholar
  21. 21.
    Kravetz D, Romero G, Bildozola M, Abecasis R, Argonz J, Gonzalez B, Calcagno J, Terg R: Nadolol plus spironolactone is not more effective than nadolol alone in decreasing portal pressure in cirrhotic patients. Hepatology 24:206A, 1996 (abstract)Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Shigeo Sugano
  • Takashi Kawafune
  • Tugio Okajima
  • Kunihiko Ishii
  • Manabu Watanabe
  • Naoko Takamura

There are no affiliations available

Personalised recommendations